Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.
Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (order Nidovirales) that causes respiratory and reproductive disease in equids. Protective, virus-neutralizing antibodies (VNAb) elicited by infection are directed predominantly against an immunodominant region in the membrane-proximal domain of the viral envelope glycoprotein G(L), allowing recently the establishment of a sensitive peptide enzyme-linked immunosorbent assay (ELISA) based on this particular domain (J. Nugent et al., J. Virol. Methods 90:167-183, 2000). By using an infectious cDNA we have now generated, in the controlled background of a nonvirulent virus, a mutant EAV from which this immunodominant domain was deleted. This virus, EAV-G(L)Delta, replicated to normal titers in culture cells, although at a slower rate than wild-type EAV, and caused an asymptomatic infection in ponies. The antibodies induced neutralized the mutant virus efficiently in vitro but reacted poorly to wild-type EAV strains. Nevertheless, when inoculated subsequently with virulent EAV, the immunized animals, in contrast to nonvaccinated controls, were fully protected against disease; replication of the challenge virus occurred briefly at low though detectable levels. The levels of protection achieved suggest that an immune effector mechanism other than VNAb plays an important role in protection against infection. As expected, infection with EAV-G(L)Delta did not induce a measurable response in our G(L)-peptide ELISA while the challenge infection of the animals clearly did. EAV-G(L)Delta or similar mutants are therefore attractive marker vaccine candidates, enabling serological discrimination between vaccinated and wild-type virus-infected animals.
Castillo-Olivares
Javier
J
Centre for Preventive Medicine, Animal Health Trust, Kentford, Newmarket, Suffolk CB8 7UU, United Kingdom.
Wieringa
Roeland
R
Bakonyi
Tamás
T
de Vries
Antoine A F
AA
Davis-Poynter
Nick J
NJ
Rottier
Peter J M
PJ
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D018174:Arterivirus Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary / Q000821:virology; D002460:Cell Line; D002478:Cells, Cultured; D006224:Cricetinae; D007240:Equartevirus / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000472:pathogenicity; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006736:Horses; D007114:Immunization; D008168:Lung / Q000166:cytology; D009500:Neutralization Tests; D017384:Sequence Deletion; D022581:Vaccines, Marker; D014759:Viral Envelope Proteins / Q000235:genetics*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D022581:Vaccines, Marker; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C105880:glycoprotein L, equine arteritis virus